In the News
World Congress: AI and Digital Twins to Drive the Next Generation Drug Discovery and Development
Watch Colin Hill’s talk at Charles River’s sixth Annual World Congress on May 11, 2023, in Cambridge, MA. Colin’s session focused on “Al and Digital Twins to Drive the Next Generation of Drug Discovery and Development”. The presentation was followed by a fireside chat with Julie Frearson, Chief Scientific Officer at Charles River Laboratories…
Servier Doubles Up on Digital Twin Alliance with Aitia
French pharma group Servier has formed a second partnership with Aitia focusing on the use of artificial intelligence and digital twins to help discover and develop new therapies for cancer.
Companies to Focus on Therapeutic Targets Showing Cause and Effect
Aitia has been featured in Huntington’s Disease News for its collaboration with UCB to develop a new treatment for Huntington’s disease. The article highlights Aitia’s expertise in Causal AI as “a new branch of artificial intelligence that goes beyond establishing links between variables: It makes decisions and predictions based on cause and effect”…
Join Aitia at the Drug Discovery Europe & Neuroscience Drug Development Europe 2023 Conference in Berlin
We are thrilled to announce that our CBO, Joe Donahue will be taking the stage at the Drug Discovery Europe & Neuroscience Drug Development Europe 2023 Conference in Berlin, Germany.
Join Aitia at the Symposium on Risks and Opportunities of AI in Pharmaceutical Medicine – AIPM 2023
Join us at the Symposium on Risks and Opportunities of AI in Pharmaceutical Medicine on June 5. We are excited to present a session entitled “Causal AI for Learning ‘Digital Twins’ from Human Multi-Omic Data for Drug Discovery and Clinical Development: A Cardiovascular Disease Case Study”…
Meet us at Bio-IT World Conference in Boston
We are thrilled to announce that Joe Donahue will be chairing a session entitled “Discover Novel Drug Candidates to Produce Better Precision Medicines” at the Bio-IT World Conference on May 18th at 10:20 ET, as part of the “AI for Drug Discovery and Development” track…
Aitia Enters into Multi-Year AI-Driven Drug Discovery and Drug Simulation Collaboration with Servier for Pancreatic Cancer
Aitia, the leader in the development and application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced a collaboration with Servier to create new Gemini Digital Twins to help in the fight against Pancreatic Cancer.
Demonstration of Accurate Screening of Gene Dependency in Multiple Myeloma from Aitia’s Gemini Digital Twins to be Presented at 2023 AACR Annual Meeting
Aitia, the leader in the application of causal AI and “Digital Twins” to discover and develop new drugs, announced today that data from its Multiple Myeloma Digital Twin model will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting.
Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington’s Disease
UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced an early drug discovery collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease.